TORONTO, Aug. 26, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the continued focus on performing electrophysiology (EP) procedures to treat atrial fibrillation (AF) will drive robust adoption of premium-priced devices that are designed exclusively for this indication. In particular, the force-sensing and alternative energy ablation catheter segments will undergo the most pronounced expansion in Europe through 2021. Companies in the EP market are recognizing the revenue potential for the AF indication, resulting in considerable competitive activity in this space.
"Having a strong portfolio of products for treating AF has become increasingly important for competitors in the EP device market," said MRG Manager Julie McLaughlin. "This has not only led to a number of technological innovations, product launches, and partnerships between companies, but has also sparked acquisition activity in this space."
A recent example is St. Jude Medical's acquisition of Switzerland-based Endosense, which sells the TactiCath, a force-sensing irrigated-tip catheter that is well-supported by clinical data and has been well-received by European physicians. The TactiCath is also designed for use alongside the EP mapping systems of large companies like GE Healthcare and Siemens Healthcare. Overall, St. Jude Medical's purchase of Endosense and this product will likely strengthen its position in the fast-growing AF treatment market.
Ultimately, the trend toward the use of more expensive advanced tools for AF treatment will help mitigate the effects of budgetary pressures in Europe that will contribute to price erosion and delayed purchases of costly EP lab systems over the next few years, allowing the European EP mapping and ablation device market to exceed $915 million by 2021.
Millennium Research Group's European Markets for Electrophysiology Mapping and Ablation Devices 2013 report includes unit, installed base, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for EP lab systems, diagnostic catheters and ablation catheters in the France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders
For more information, contact:Christopher Comfort
Alex JablokowDecision Resources Group
Millennium Research Group781-993-2597
|SOURCE Millennium Research Group|
Copyright©2012 PR Newswire.
All rights reserved